By Lecia Bushak |
December 13th, 2019
Biogen has announced new data behind the Alzheimer's drug aducanumab suggests it was working on early stage patients. Jeff Borghoff was a participant for three years before the company halted the stage three clinical trial. He talks to Being Patient Alzheimer's about why he felt the drug was working.
If you find our articles and interviews helpful, please consider becoming a supporting member of our community.
Frustrated by the lack of an editorially independent source of information on brain health and Alzheimer’s disease, we decided to create Being Patient.
We are a team of dedicated journalists covering the latest research on Alzheimer’s, bringing you access to the experts and elevating the patient perspective on what it’s like to live with dementia.
Please help support our mission.